Results 191 to 200 of about 154,404 (310)

Do the pharmacokinetics of statins explain psychiatric symptom improvement from adjunctive statin prescribing in severe mental illness? Three target trial emulation studies. [PDF]

BMJ Ment Health
Launders N, Richards-Belle A, Hardoon S, Man K, Wong ICK, Osborn DPJ, Hayes JF.   +6 more
europepmc   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

Med Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang, Ge Zhang, Tian‐Ding Liu, Tianshu Gu, Fengyi Yu, Pengyuan Xu, Wunan Mi, Xuanjiang Zhao, Qian Guo, Honglin Zheng, Taiqi Zhao, Qiang Li, Di Lu, Mingxuan Duan, Chaoyang Yu, Ruhao Wu, Shiqian Zhang, Haonan Zhang, Zeyu Wang, Youyang Zheng, Yan Xiao, Zenglei Zhang, Ge Zhang   +22 more
wiley   +1 more source

The Contribution of Cholesterol and Squalene Synthase in Cancer: Molecular Mechanisms, Lipid Rafts and Therapeutic Approaches

Medicinal Research Reviews, EarlyView.
ABSTRACT A plethora of cellular signaling pathways are dysregulated in cancer cells, promoting carcinogenesis and migration. Cholesterol has recently been linked to cancer by several subcellular mechanisms, especially by its involvement in the formation of lipid rafts, which promote oncogenic signaling and cancer cell invasion. Squalene synthase (SQS),
Danai Mavridi, Theodora Katavati, Angeliki P. Kourounakis   +2 more
wiley   +1 more source

Biochemical urine analysis of atorvastatin and rosuvastatin by LC-MS: a pilot study of an objective method to assess non-adherence. [PDF]

BMC Cardiovasc Disord
Brockmeyer M, Chernyak N, Dröge D, Wessel H, Parco C, Hoss A, Vargas KG, Lin Y, Rickert A, Ritz S, Icks A, Kelm M, Wolff G, Temme O.   +13 more
europepmc   +1 more source

Human Cyclophilins—An Emerging Class of Drug Targets

Medicinal Research Reviews, EarlyView.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova, Hana Navratilova, Kamil Musilek, Ondrej Benek   +3 more
wiley   +1 more source

Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries. [PDF]

Cost Eff Resour Alloc
Azari S, Pourasghari H, Rezaei MA, Behzadifar M, Salehbeigi S, Rajaei S, Jafarzadeh D, Soleimanpour S, Tajdini M.   +8 more
europepmc   +1 more source

Nanoformulated Diacerein Alleviates Hyperlipidemia via Gut Microbiota Modulation In Vivo

Nano Select, EarlyView.
A nanoformulation of diacerein (Nano‐DIA) was fabricated with carboxymethyl cellulose, achieving enhanced solubility and rapid dissolution for alternative anti‐hyperlipidemia therapeutics. Mechanistic studies revealed its in vivo lipid‐lowering efficacy is through metabolite‐mediated and microbiota‐dependent manner, highlighting its dual action on host
Zheng Peng, Yi Yu, Mingyi Chen, Weibin Wu, Chunyan Zhu, Caisheng Wu, Weihua Li, Zehua Liu, Qiang Xie   +8 more
wiley   +1 more source

Pharmacological strategies for preventing post-stroke seizures and epilepsy. [PDF]

Front Neurol
Kawamura Y, Trinka E, Quinn TJ, Emsley HCA, Zelano J, Tanaka T, Ihara M, Sansing LH, Liebeskind DS, Mishra NK.   +9 more
europepmc   +1 more source

Association of Glucagon‐Like Peptide‐1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes

Obesity, EarlyView.
ABSTRACT Objective The real‐world evidence on the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and cancer risk remains limited and mixed. Methods In 2013–2020 national Medicare claims data, we included cancer‐naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP‐1 RA, sodium‐glucose cotransporter 2
Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian   +13 more
wiley   +1 more source

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. [PDF]

Eur Heart J Qual Care Clin Outcomes
Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J.   +6 more
europepmc   +1 more source